Date: Wednesday April 6, 2016 
Time: 10AM PST | 1PM EST | 6PM GMT
Duration: 1 hour
Complementary and open to life science professionals globally

Click here to register

Overview: 

Cancer continues to be a leading cause of morbidity and mortality worldwide with more than 8 million deaths and 14 million new cases per year.  Significant advances have been made to unravel cancer’s mysteries and complexities at the genetic-, molecular- and pathway-levels. These advances not only reveal new scientific insights into the biology of the diseases, but also herald a new era with fresh perspectives for prevention, diagnosis, and more effective, precision-driven therapies.  In this complimentary live webinar, open to life science professionals globally, WuXi brings together scientific and executive leaders from the pharma, biotech and the venture capital communities to discuss “Pioneering Approaches to Dismantling Cancer.”

Speakers:

James Audia, CSO, Constellation Pharmaceuticals
Philip Gotwals, Executive Director, Exploratory Immuno-Oncology, Novartis Institutes of BioMedical Research
Jason Rhodes, Partner, Atlas Venture
Richard Soll, SVP, International Discovery Service Unit, WuXi AppTec (Moderator)

Speaker Bio:

James Audia, PhD, CSO, Constellation Pharmaceuticals

Dr. Jim Audia joined Constellation in January 2011 following a highly productive career in drug discovery at Eli Lilly and Company. Dr. Audia held several key leadership roles during his 23-year tenure at Lilly. As a Distinguished Lilly Scholar, the highest level of the company’s scientific ladder, he made seminal technical and strategic contributions to the Lilly drug pipeline. Prior to this role, Dr. Audia was Executive Director, Discovery Chemistry Research and Technologies, where he had global responsibility for delivery of small molecule drug candidates across all therapeutic areas. He also played a major role in companywide leadership of product strategy and portfolio management for Lilly for more than a decade. Over the course of his career, Dr. Audia’s scientific work has contributed to more than 12 development candidates, including transformative contributions to the treatment of Alzheimer’s disease through his discovery of both the first gamma secretase inhibitor and an industry-leading beta secretase inhibitor. Dr. Audia is a named inventor on more than 90 issued US patents and has published and presented extensively. He received his Ph.D. in Organic Chemistry from the University of South Carolina and did postdoctoral training at Yale University before joining Lilly.

Philip Gotwals, PhD, Executive Director, Exploratory Immuno-Oncology, Novartis Institutes of BioMedical Research

Dr. Philip Gotwals is currently Executive Director, Exploratory Immuno-Oncology, at Novartis Institutes of BioMedical Research, and has been instrumental in building the immune-oncology strategic research area including the collaboration with the University of Pennsylvania to develop CAR-T cell therapy.  Dr. Gotwals has over 20 years of experience in the biotechnology and pharmaceutical industries leading internal and collaborative research and development programs from discovery to NDA filing, and participating in the licensing of product candidates.  Dr. Gotwals is the former Vice President, Project Management at Altus Pharmaceuticals responsible for all product development project management activities. Prior to his engagement at Altus, Dr. Gotwals was Senior Director, Program and Alliance Management at Biogen where he oversaw leadership of internal and allied early product development teams in the autoimmune, neurology and oncology therapeutic areas including work on rituximab (Rituxan®) and natalizumab (Tysabri®).  Dr. Gotwals holds a PhD in Genetics from the University of California at Berkeley, completed post-doctoral research at the Massachusetts Institute of Technology, and has published extensively in the area of integrin biology.

Jason Rhodes, Partner, Atlas Venture

Jason Rhodes is a partner and focuses on the creation, development, and business strategy of novel therapeutics companies.  Mr. Rhodes is on the board of Replimune, Bicycle Therapeutics, and Raze Therapeutics.  Prior to joining Atlas Venture in 2014, Mr. Rhodes was president and chief financial officer of Epizyme (NASDAQ: EPZM). Mr. Rhodes joined Epizyme when it was a private, research-stage company and was instrumental in charting the company’s strategic course and building the business, leading to Epizyme’s successful IPO in 2013. He established and was responsible for all business functions and led the company’s partnerships with Celgene, GSK, and Eisai, raising more than $180 million in non-equity funding while retaining U.S. product rights.  Prior to Epizyme, Mr. Rhodes was vice president of business development at Alnylam (NASDAQ: ALNY), where he led corporate partnerships with companies including Takeda, GSK, Isis, Cubist, Roche, Kyowa Hakko Kirin, and Medtronic as well as the spin out of Regulus Therapeutics (NASDAQ: RGLS). Together, these partnerships brought in more than $200 million in non-equity funding.  Before joining Alnylam, Mr. Rhodes was a founder and partner with Fidelity Biosciences, the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including Ironwood Pharmaceuticals (NASDAQ: IRWD), FoldRx (purchased by Pfizer), and Tetraphase (NASDAQ: TTPH).

Earlier in his career, Mr. Rhodes worked on new business entrance, product strategy, and commercialization projects with biopharma and high tech companies.  Mr. Rhodes  received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania.  He is a member of the Berklee College of Music Presidential Advisory Council.

Richard Soll, PhD, SVP, International Discovery Service Unit, WuXi AppTec

Dr. Richard Soll is Senior Vice President of the International Discovery Service Unit (IDSU) at WuXi AppTec. In this capacity, Dr. Soll leads the discovery synthetic- and medicinal-chemistry global collaborations at WuXi that aim to provide expertise and innovative solutions for small molecule drug R&D across biopharma and life science industries. In addition, Dr. Soll’s expanded responsibilities include oversight of the newly established WuXi offices in Cambridge, Massachusetts and Israel.  These offices bring WuXi’s comprehensive platform of integrated R&D services closer to innovative companies and entrepreneurs in the world’s two leading biotech hubs. Prior to WuXi, Dr. Soll was CSO and VP of R&D at TargeGen where he led multiple clinical stage R&D programs. Dr. Soll founded the chemistry department at 3-Dimensional Pharmaceuticals as VP of Chemistry. Dr. Soll began his industry career at Wyeth Pharmaceuticals and was trained as a synthetic chemist at Dartmouth and Harvard. Dr. Soll’s drug discovery and development experiences has led to more than 100 patents and papers, and more than 10 drug candidates advancing to the clinic including drugs of breakthrough designation. Dr. Soll has been an SAB member to biotech companies and advisor to entrepreneurs.

Submit your questions in advance for speakers during registration!